Potassium Permanganate

證據等級: L5

預測適應症: 10 個

Potassium Permanganate: Original Indication Undocumented — Assessment of Predicted New Indications

One-Sentence Summary

Potassium permanganate (DrugBank DB13831) has no original indication or mechanism-of-action data available in the current evidence pack, and the drug is not marketed in Australia (0 ARTG entries). TxGNN’s model predicts 10 candidate indications, the highest-ranked being Benign Prostatic Hyperplasia (97.66% prediction score), but the drug’s own repurposing rationale flags the supporting literature as keyword coincidence rather than genuine mechanistic evidence — none of the 10 candidates currently clears an evidentiary bar to proceed.

Quick Overview

Item	Content
Original Indication	Not documented in available regulatory data
Predicted New Indication	Benign Prostatic Hyperplasia (top-ranked of 10 candidates)
TxGNN Prediction Score	97.66%
Evidence Level	L5
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for potassium permanganate in this evidence pack, and no original indication is recorded either. Without a documented pharmacological baseline, it is not possible to construct a mechanistic bridge between an existing use and the top predicted indication (Benign Prostatic Hyperplasia).

More importantly, the evidence review for this candidate explicitly concludes the link is not genuine: the two supporting PubMed articles concern prostatic corpora amylacea and seminal vesicle amyloidosis, topics unrelated to potassium permanganate’s pharmacology or to BPH treatment. The reviewer’s own assessment characterises this as a keyword coincidence (both articles happen to reference prostate pathology) rather than a real repurposing signal.

This pattern repeats across the other nine candidates in the pack — none has a coherent mechanistic rationale, and one candidate (osteoarthritis, rank 4) has literature that runs in the opposite direction: a 1979 study used potassium permanganate to induce a crystal-deposition disease model, which would argue against, not for, therapeutic use in osteoarthritis.

Predicted Indications — Full Candidate Summary

Given that all 10 TxGNN-predicted candidates carry weak or contradictory evidence, the full ranked list is provided for transparency rather than focusing on the top candidate alone:

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation	Note
1	Benign prostatic hyperplasia	97.66%	L5	Hold	Literature is keyword coincidence, not mechanistic
2	Alopecia	97.17%	L5	Hold	No literature or trials
3	Congestive heart failure	96.86%	L5	Hold	5 literature hits, all unrelated topics
4	Osteoarthritis	96.71%	L4	Hold	Evidence points opposite direction (disease-induction model, not treatment)
5	Hypotrichosis simplex of the scalp	96.62%	L5	Hold	No literature or trials; rare genetic disease
6	Congenital hypotrichosis milia	96.48%	L5	Hold	No literature or trials; rare genetic disease
7	Osteoarthritis susceptibility	96.27%	L5	Hold	No literature or trials
8	Acute pulmonary heart disease	96.13%	L5	Hold	No literature or trials
9	Pulmonary hypertension	95.99%	L5	Hold	2 literature hits, unrelated topics
10	Diffuse alopecia areata	95.87%	L5	Hold	No literature or trials

Clinical Trial Evidence (Rank 1: Benign Prostatic Hyperplasia)

Currently no related clinical trials registered.

Literature Evidence (Rank 1: Benign Prostatic Hyperplasia)

PMID	Year	Type	Journal	Key Findings
1385482	1992	Case study/Pathology	Journal of Clinical Pathology	Immunohistological study of amyloid in prostatic corpora amylacea; not a treatment or KMnO4-related study
9431316	1997	Case report	Archives of Pathology & Laboratory Medicine	Localized seminal vesicle amyloidosis in hormonally treated prostate carcinoma patients; not a treatment or KMnO4-related study

Neither article discusses potassium permanganate or a treatment mechanism for BPH — both were captured on prostate-related keyword overlap only.

Australia Market Information

No ARTG entries currently found. Potassium permanganate is not marketed in Australia under this evidence pack’s regulatory data (0 licences recorded).

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. No key warnings, contraindications, or drug interaction data were located for potassium permanganate in the sources queried (DDI database search returned no result).

Conclusion and Next Steps

Decision: Hold

Rationale: No original indication, mechanism-of-action, or safety data exists for potassium permanganate in this evidence pack, and none of the 10 TxGNN-predicted candidates is supported by genuine clinical or mechanistic evidence — the top candidate’s literature was assessed by the review itself as coincidental keyword matches, and one candidate’s evidence points against therapeutic benefit.

To proceed, the following is needed:

TFDA/TGA-approved Product Information (labelled warnings, contraindications) — currently a Blocking data gap
Verified mechanism of action from DrugBank or primary literature
A documented original/established indication for baseline comparison
Real clinical trial or high-quality literature evidence specific to any candidate indication before advancing past S0/S1
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.